Literature Review: Moving the Druggable Needle
The Use of an mRNA Display Technology and Affinity-Based Selection Is Used to Find Inhibitors to an Enzyme of Interest
To Surge or Not to Surge?
Experts Discuss Inclusion of a Surge Tank in an End-to-End Continuous Biomanufacturing Train
New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
- Cresset Group
- BioPark Hertfordshire, Broadwater Road
- Welwyn Garden City
- Herts , AL7 3AX
- UNITED KINGDOM
Cresset was formed in 2002 using the basic research of our founder Dr Andy Vinter to introduce a new virtual screening technology. Over the last decade our technology has been widely adopted throughout the drug discovery and agrochemical industries.